Molgramostim Completed Phase 3 Trials for Pulmonary Alveolar Proteinosis, Autoimmune Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT03482752Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis